Mike Doustdar

Great assets, but complementary.

Okay, so why do you need complementary assets?

Because you've got all these products.

Why do you need to go and buy this business?

Because obesity and diabetes is not a single disease.

It's an individual disease.

You basically have different preferences.

Take a look at the great Vigovi pill we are about to launch in US.

Well, that's for people that don't like injection.

They would like to lose weight, but they don't have a viable offering from us or the competitors.

You've got very similar products.

And the question that I've listened to a lot of analysts, talked to a lot of analysts, and the question they keep coming up with is, does this seem to signal maybe that you don't believe in the current Novo portfolio?

Absolutely not.

Absolutely not.

We are in a situation where every single patient has a different preference.

And we need to have the product offering that matches that.

They've got a monthly, you've got a weekly.

Is that really the big difference?

Well, we saw that the weekly was a big difference to the daily one.

So I would say for some... So monthly does make a difference?